Lipofectamine 2000 drug
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (9)
Papers in which this entity is mentioned.
- Neuroprotective Peptide NAPVSIPQ Antagonizes Ethanol Inhibition of L1 Adhesion by Promoting the Dissociation of L1 and Ankyrin-G. (2020)
- Reciprocal monoallelic expression of ASAR lncRNA genes controls replication timing of human chromosome 6. (2020)
- Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. (2018)
- Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. (2018)
- A role for human homologous recombination factors in suppressing microhomology-mediated end joining. (2016)
- The cell cycle regulator CCDC6 is a key target of RNA-binding protein EWS. (2015)
- Comprehensive genomic profiles of small cell lung cancer. (2015)
- Mitogen-activated protein kinase modulates ethanol inhibition of cell adhesion mediated by the L1 neural cell adhesion molecule. (2013)
- Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges. (2013)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| lipofectamine 2000 | drug | 34 | 44 |
| lipofectamine 2000 (life technologies, inc.) | drug | — | — |